Kalpress Plus Forte

Valsartan, the active ingredient in Kalpress Plus Forte, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. In combination with hydrochlorothiazide, a thiazide diuretic, the formulation lowers blood pressure by reducing vascular resistance and plasma volume, providing a convenient dual‑action therapy for adults with primary hypertension.

GNH USA supplies Kalpress Plus Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across EU and other markets.

Kalpress Plus Forte combines an ARB and a thiazide diuretic to treat hypertension, a major cardiovascular risk factor.

- Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of stroke and heart attack.

Kalpress Plus Forte may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Increased urination: due to the diuretic component. - Electrolyte imbalance: low potassium or sodium levels. - Fatigue: general feeling of tiredness. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Hyperkalemia: elevated potassium that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: marked drop in blood pressure causing fainting. - Allergic reaction: rash, itching, or swelling of the face and throat.

Before initiating therapy with Kalpress Plus Forte, several safety considerations should be reviewed.

- Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte assessment: check potassium and sodium levels, especially in patients on other diuretics. - Blood pressure checks: ensure adequate control without excessive hypotension. - Pregnancy safety: avoid use unless benefits outweigh potential risks, as safety data are limited. - Drug-specific contraindications: do not use in patients with known hypersensitivity to either component. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Kalpress Plus Forte can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or aliskiren: risk of additive renal impairment and hyperkalemia. - Lithium: increased lithium levels may cause toxicity. - NSAIDs: may blunt antihypertensive effect and affect renal function. - Potassium‑sparing diuretics: can precipitate dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause excessive blood pressure reduction. - Antidiabetic agents: enhanced hypoglycemic effect. - CYP3A4 inhibitors (e.g., ketoconazole): may raise valsartan concentrations. - CYP2C9 substrates (e.g., warfarin): possible alteration of anticoagulant effect.